CoChat
Sign Up
Cited by 10Urticaria and Related ConditionsDermatology and Skin DiseasesChronic Disease Management Strategies

A Patient Charter for Chronic Urticaria

Open access
Maurer, Marcus, Albuquerque, Mónica, Boursiquot, Jean-Nicolas, Dery, Elaine, Giménez-Arnau, Ana, Godse, Kiran, Guitiérrez, Guillermo, Kanani, Amin +4 more·2024·Advances in Therapy
DOI 10.1007/s12325-023-02724-6PMC PMC10796664
Open this paper in CoChat — free accountOpen PDF

Abstract

Chronic urticaria (CU) is the recurring development of wheals (aka "hives" or "welts"), angioedema, or both for more than 6 weeks. Wheals and angioedema occur with no definite triggers in chronic spontaneous urticaria, and in response to known and definite physical triggers in chronic inducible urticaria. Approximately 1.4% of individuals globally will have CU during their lifetime. The itching and physical discomfort associated with CU have a profound impact on daily activities, sexual function, work or school performance, and sleep, causing significant impairment in a patient's physical and mental quality of life. CU also places a financial burden on patients and healthcare systems. Patients should feel empowered to self-advocate to receive the best care. The voice of the patient in navigating the journey of CU diagnosis and management may improve patient-provider communication, thereby improving diagnosis and outcomes. A collaboration of patients, providers, advocacy organizations, and pharmaceutical representatives have created a patient charter to define the realistic and achievable principles of care that patients with CU should expect to receive. Principle (1): I deserve an accurate and timely diagnosis of my CU; Principle (2): I deserve access to specialty care for my CU; Principle (3): I deserve access to innovative treatments that reduce the burden of CU on my daily life; Principle (4): I deserve to be free of unnecessary treatment-related side-effects during the management of my CU; and Principle (5): I expect a holistic treatment approach to address all the components of my life impacted by CU. The stated principles may serve as a guide for healthcare providers who care for patients with CU and translate into better patient-physician communication. In addition, we urge policymakers and authors of CU treatment guidelines to consider these principles in their decision-making to ensure the goals of the patient are achievable.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-023-02724-6

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 69

  1. [1]Zuberbier T Abdul Latiff AH Abuzakouk M Aquilina S Asero R Baker D The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria Allergy 2022 77 734 766 10.1111/all.15090 34536239 · DOI · Paper page
  2. [2]Kolkhir P Pogorelov D Darlenski R Caminati M Tanno LK Le Pham D Management of chronic spontaneous urticaria: a worldwide perspective World Allergy Organ J 2018 11 14 10.1186/s40413-018-0193-4 29988758 PMC6030778 · DOI
  3. [3]Bernstein JA Lang DM Khan DA Craig T Dreyfus D Hsieh F The diagnosis and management of acute and chronic urticaria: 2014 update J Allergy Clin Immunol 2014 133 1270 1277 10.1016/j.jaci.2014.02.036 24766875 · DOI
  4. [4]Fricke J Ávila G Keller T Weller K Lau S Maurer M Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis Allergy 2020 75 423 432 10.1111/all.14037 31494963 · DOI · Paper page
  5. [5]Sánchez-Borges M Ansotegui IJ Baiardini I Bernstein J Canonica GW Ebisawa M The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management World Allergy Organ J 2021 14 100533 10.1016/j.waojou.2021.100533 34221215 PMC8233382 · DOI
  6. [6]Gonçalo M Gimenéz-Arnau A Al-Ahmad M Ben-Shoshan M Bernstein JA Ensina LF The global burden of chronic urticaria for the patient and society Br J Dermatol 2021 184 226 236 10.1111/bjd.19561 32956489 · DOI
  7. [7]Maurer M Weller K Bindslev-Jensen C Giménez-Arnau A Bousquet PJ Bousquet J Unmet clinical needs in chronic spontaneous urticarial. A GA2LEN task force report Allergy 2011 66 317 330 10.1111/j.1398-9995.2010.02496.x 21083565 · DOI · Paper page
  8. [8]Sánchez-Borges M Ansotegui IJ Baiardini I Bernstein J Canonica GW Ebisawa M The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations World Allergy Organ J 2021 14 100546 10.1016/j.waojou.2021.100546 34141049 PMC8188551 · DOI
  9. [9]Silpa-archa N Kulthanan K Pinkaew S Physical urticaria: prevalence, type and natural course in a tropical country J Eur Acad Dermatol Venereol 2011 25 1194 1199 10.1111/j.1468-3083.2010.03951.x 21175877 · DOI
  10. [10]Maurer M Abuzakouk M Bérard F Canonica W Oude Elberink H Giménez-Arnau A The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU Allergy 2017 72 2005 2016 10.1111/all.13209 28543019 PMC5724512 · DOI · Paper page
  11. [11]Balp MM Vietri J Tian H Isherwood G The impact of chronic urticaria from the patient's perspective: a survey in five European countries Patient 2015 8 551 558 10.1007/s40271-015-0145-9 26476961 PMC4662955 · DOI
  12. [12]Hoskin B Ortiz B Paknis B Kavati A Humanistic burden of refractory and nonrefractory chronic idiopathic urticaria: a real-world study in the United States Clin Ther 2019 41 205 220 10.1016/j.clinthera.2018.12.004 30606639 · DOI
  13. [13]Huang Y Xiao Y Zhang X Li J Chen X Shen M A meta-analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety Front Med (Lausanne) 2020 7 39 10.3389/fmed.2020.00039 32175322 PMC7056669 · DOI · Paper page
  14. [14]Goldstein S Eftekhari S Mitchell L Winders TA Kaufman L Dudas D Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US Acta Derm Venereol 2019 99 1091 1098 31396637
  15. [15]Tomaszewska K Słodka A Tarkowski B Zalewska-Janowska A Neuro-immuno-psychological aspects of chronic urticaria J Clin Med 2023 12 3134 10.3390/jcm12093134 37176575 PMC10179371 · DOI
  16. [16]Williams P Kavati A Pilon D Xiao Y Zhdanava M Balp MM Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: a real-world study in the United States Allergy Asthma Proc 2018 39 201 211 10.2500/aap.2018.39.4129 29514728 · DOI
  17. [17]Fein MN Fischer DA O'Keefe AW Sussman GL CSACI position statement: Newer generation H(1)-antihistamines are safer than first-generation H(1)-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria Allergy Asthma Clin Immunol 2019 15 61 10.1186/s13223-019-0375-9 31582993 PMC6771107 · DOI
  18. [18]Caffarelli C Paravati F El Hachem M Duse M Bergamini M Simeone G Management of chronic urticaria in children: a clinical guideline Ital J Pediatr 2019 45 101 10.1186/s13052-019-0695-x 31416456 PMC6694633 · DOI
  19. [19]Chung WH Chu CY Huang YH Wang WM Yang CH Tsai TF Taiwanese dermatological association consensus for the definition, classification, diagnosis, and management of urticaria J Formos Med Assoc 2016 115 968 980 10.1016/j.jfma.2015.09.009 26679383 · DOI
  20. [20]Hacard F Giraudeau B d'Acremont G Jegou MH Jonville-Bera AP Munck S Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the centre of evidence of the french society of dermatology Br J Dermatol 2021 185 658 660 10.1111/bjd.20415 33913519 PMC8457139 · DOI
  21. [21]Powell RJ Leech SC Till S Huber PA Nasser SM Clark AT BSACI guideline for the management of chronic urticaria and angioedema Clin Exp Allergy 2015 45 547 565 10.1111/cea.12494 25711134 · DOI
  22. [22]Esteves Caldeira L Paulino M Coutinho C Neto M Pereira Barbosa M Costa C Clinical experience of a specialized urticaria outpatient clinic from a Portuguese UCARE Eur Ann Allergy Clin Immunol 2023 55 9 18 10.23822/EurAnnACI.1764-1489.209 33949172 · DOI
  23. [23]Maurer M Weller K Magerl M Maurer RR Vanegas E Felix M The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: a UCARE study World Allergy Organ J 2020 13 100475 10.1016/j.waojou.2020.100475 33204387 PMC7606865 · DOI
  24. [25]Bansal CJ Bansal AS Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria Allergy Asthma Clin Immunol 2019 15 56 10.1186/s13223-019-0372-z 31528163 PMC6737621 · DOI
  25. [26]Zuberbier T Pfrommer C Specht K Vieths S Bastl-Borrmann R Worm M Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria J Allergy Clin Immunol 2002 109 343 348 10.1067/mai.2002.121309 11842307 · DOI
  26. [27]Mathelier-Fusade P Drug-induced urticarias Clin Rev Allergy Immunol 2006 30 19 23 10.1385/CRIAI:30:1:019 16461991 · DOI
  27. [28]Magerl M Altrichter S Borzova E Giménez-Arnau A Grattan CE Lawlor F The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision Allergy 2016 71 780 802 10.1111/all.12884 26991006 · DOI
  28. [29]Shaker M Oppenheimer J Wallace D Lang DM Rambasek T Dykewicz M Optimizing value in the evaluation of chronic spontaneous urticaria: a cost-effectiveness analysis J Allergy Clin Immunol Pract 2020 8 2360 9.e1 10.1016/j.jaip.2019.11.004 31751758 · DOI
  29. [30]Oliver ET Hogan MB Eliminating low-value medical care in chronic spontaneous urticaria J Allergy Clin Immunol Pract 2020 8 2370 2371 10.1016/j.jaip.2020.04.065 32620436 PMC11615728 · DOI
  30. [31]Maurer M Magerl M Metz M Siebenhaar F Weller K Krause K Practical algorithm for diagnosing patients with recurrent wheals or angioedema Allergy 2013 68 816 819 10.1111/all.12153 23646863 · DOI
  31. [32]Ryan D Tanno LK Angier E Clark E Price D Zuberbier T Clinical review: the suggested management pathway for urticaria in primary care Clin Transl Allergy 2022 12 e12195 10.1002/clt2.12195 36225262 PMC9533216 · DOI
  32. [33]Ryan D Angier E Gomez M Church D Batsiou M Nekam K Results of an allergy educational needs questionnaire for primary care Allergy 2017 72 1123 1128 10.1111/all.13134 28122131 · DOI
  33. [34]Cho YT Pao YC Chu CY Unmet medical needs for chronic spontaneous urticaria patients: highlighting the real-life clinical practice in Taiwan J Eur Acad Dermatol Venereol 2016 30 41 49 10.1111/jdv.13357 26428436 · DOI
  34. [35]Cherrez A Maurer M Weller K Calderon JC Simancas-Racines D Cherrez OI Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador World Allergy Organ J 2017 10 21 10.1186/s40413-017-0150-7 28546850 PMC5440895 · DOI
  35. [36]Weller K Viehmann K Bräutigam M Krause K Siebenhaar F Zuberbier T Management of chronic spontaneous urticaria in real life–in accordance with the guidelines? A cross-sectional physician-based survey study J Eur Acad Dermatol Venereol 2013 27 43 50 10.1111/j.1468-3083.2011.04370.x 22150693 · DOI
  36. [37]Maurer M Metz M Bindslev-Jensen C Bousquet J Canonica GW Church MK Definition, aims, and implementation of GA(2) LEN urticaria centers of reference and excellence Allergy 2016 71 1210 1218 10.1111/all.12901 27038243 · DOI
  37. [38]Maurer M Staubach P Raap U Richter-Huhn G Baier-Ebert M Chapman-Rothe N ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice Br J Dermatol 2016 174 892 894 10.1111/bjd.14203 26406483 · DOI
  38. [39]Anto A Maurer R Gimenez-Arnau A Cherrez-Ojeda I Hawro T Magerl M Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need Allergy 2021 76 3810 3813 10.1111/all.15061 34437706 · DOI
  39. [41]Maurer M Rosén K Hsieh HJ Saini S Grattan C Gimenéz-Arnau A Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria N Engl J Med 2013 368 924 935 10.1056/NEJMoa1215372 23432142 · DOI
  40. [42]Tharp MD Bernstein JA Kavati A Ortiz B MacDonald K Denhaerynck K Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of "Real-world" evidence JAMA Dermatol 2019 155 29 38 10.1001/jamadermatol.2018.3447 30427977 PMC6439579 · DOI
  41. [43]Yosipovitch G Biazus Soares G Mahmoud O Current and emerging therapies for chronic spontaneous urticaria: a narrative review Dermatol Ther (Heidelb). 2023 10.1007/s13555-023-00972-6 37386330 PMC10366054 · DOI
  42. [44]Maurer M Eyerich K Eyerich S Ferrer M Gutermuth J Hartmann K Urticaria: collegium internationale allergologicum (CIA) Update 2020 Int Arch Allergy Immunol 2020 181 321 333 10.1159/000507218 32224621 PMC7265766 · DOI
  43. [45]Hopkinson K The role of patient-reported outcomes in the management of chronic spontaneous urticaria Br J Nurs 2019 28 144 150 10.12968/bjon.2019.28.3.144 30746981 · DOI
  44. [46]Baiardini I Fasola S Maurer M Weller K Canonica GW Braido F Minimal important difference of the chronic urticaria quality of life questionnaire (CU-Q2oL) Allergy 2019 74 2542 2544 10.1111/all.13939 31169906 · DOI
  45. [47]Kulthanan K Chularojanamontri L Tuchinda P Rujitharanawong C Baiardini I Braido F Minimal clinical important difference (MCID) of the Thai chronic urticaria quality of life questionnaire (CU-Q2oL) Asian Pac J Allergy Immunol 2016 34 137 145 27007835
  46. [48]Prosty C Gabrielli S Mule P Noorah N Baum S Greenberger S Validation of the urticaria control test (UCT) in children with chronic urticaria J Allergy Clin Immunol Pract 2022 10 3293–8 e2 35973527
  47. [49]Baiardini I Braido F Bindslev-Jensen C Bousquet PJ Brzoza Z Canonica GW Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper Allergy 2011 66 840 844 10.1111/j.1398-9995.2011.02580.x 21385184 · DOI
  48. [50]Weller K Siebenhaar F Hawro T Altrichter S Schoepke N Maurer M Clinical measures of chronic urticaria Immunol Allergy Clin North Am 2017 37 35 49 10.1016/j.iac.2016.08.005 27886909 · DOI
  49. [51]Ruft J Asady A Staubach P Casale T Sussmann G Zuberbier T Development and validation of the cholinergic urticaria quality-of-life questionnaire (CholU-QoL) Clin Exp Allergy 2018 48 433 444 10.1111/cea.13102 29369455 · DOI
  50. [52]Ahsan DM Altrichter S Gutsche A Bernstein JA Altunergil T Brockstaedt M Development of the cold urticaria activity score Allergy 2022 77 2509 2519 10.1111/all.15310 35403217 · DOI
  51. [54]Fok JS Kolkhir P Church MK Maurer M Predictors of treatment response in chronic spontaneous urticaria Allergy 2021 76 2965 2981 10.1111/all.14757 33539587 · DOI
  52. [55]Weller K Ohanyan T Hawro T Ellrich A Sussman G Koplowitz J Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab Allergy 2018 73 2406 2408 10.1111/all.13586 30076605 · DOI
  53. [56]Deza G Bertolin-Colilla M Pujol RM Curto-Barredo L Soto D Garcia M Basophil fcepsilonri expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy Acta Derm Venereol 2017 97 698 704 10.2340/00015555-2654 28303277 · DOI
  54. [57]Curto-Barredo L Archilla LR Vives GR Pujol RM Giménez-Arnau AM Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment Acta Derm Venereol 2018 98 641 647 10.2340/00015555-2941 29648675 · DOI
  55. [58]Church MK Maurer M Simons FE Bindslev-Jensen C van Cauwenberge P Bousquet J Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper Allergy 2010 65 459 466 10.1111/j.1398-9995.2009.02325.x 20146728 · DOI · Paper page
  56. [59]Simons FE Simons KJ Histamine and H1-antihistamines: celebrating a century of progress J Allergy Clin Immunol 2011 128 1139–50 e4 22035879
  57. [60]Gilmore TM Alexander BH Mueller BA Rivara FP Occupational injuries and medication use Am J Ind Med 1996 30 234 239 10.1002/(SICI)1097-0274(199608)30:2<234::AID-AJIM16>3.0.CO;2-Y 8844055 · DOI
  58. [61]Zhou P Zeng S Fu L Chen H Li L Efficacy and safety of intensive nonsedating antihistamines for chronic spontaneous urticaria: a meta-analysis of randomized controlled trials Int Arch Allergy Immunol 2022 183 796 803 10.1159/000521900 35144258 · DOI
  59. [62]Weller K Ziege C Staubach P Brockow K Siebenhaar F Krause K H 1 -antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects – a retrospective survey study PLoS ONE 2011 6 e23931 10.1371/journal.pone.0023931 21909407 PMC3164658 · DOI
  60. [63]Tayefi M Bradley M Neijber A Fastberg A Ceynowa D Eriksson M Chronic urticaria: a Swedish registry-based cohort study on population, comorbidities and treatment characteristics Acta Derm Venereol 2022 102 adv00624 10.2340/actadv.v101.737 34877606 PMC9631294 · DOI
  61. [64]Lachover-Roth I Rabie A Cohen-Engler A Rosman Y Meir-Shafrir K Confino-Cohen R Chronic urticaria in children - new insights from a large cohort Pediatr Allergy Immunol 2021 32 999 1005 10.1111/pai.13457 33502063 · DOI
  62. [65]Torre AC Bollea Garlatti ML Marciano S Posadas-Martinez ML Parisi CAS Mazzuoccolo LD Real-life approach and treatment of chronic urticaria in Argentina: a national survey Dermatol Ther 2019 32 e13086 10.1111/dth.13086 31513726 · DOI
  63. [66]Price DB Trudo F Voorham J Xu X Kerkhof M Ling Zhi Jie J Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study J Asthma Allergy. 2018 11 193 204 10.2147/JAA.S176026 30214247 PMC6121746 · DOI
  64. [68]Menzies-Gow A Jackson DJ Al-Ahmad M Bleecker ER Cosio Piqueras FBG Brunton S A renewed charter: key principles to improve patient care in severe asthma Adv Ther 2022 39 5307 5326 10.1007/s12325-022-02340-w 36251167 PMC9573814 · DOI
  65. [70]Özkan M Oflaz SB Kocaman N Özşeker F Gelincik A Büyüköztürk S Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria Ann Allergy Asthma Immunol 2007 99 29 33 10.1016/S1081-1206(10)60617-5 17650826 · DOI
  66. [71]Picardi A Mazzotti E Pasquini P Prevalence and correlates of suicidal ideation among patients with skin disease J Am Acad Dermatol 2006 54 420 426 10.1016/j.jaad.2005.11.1103 16488292 · DOI
  67. [72]Ogłodek EA Szota AM Just MJ Araszkiewicz A Szromek AR Sense of alexithymia in patients with anxiety disorders comorbid with recurrent urticaria Neuropsychiatr Dis Treat 2016 12 995 1004 10.2147/NDT.S94600 27143899 PMC4844460 · DOI
  68. [73]Sommer R da Silva N Langenbruch A Maurer M Staubach-Renz P Augustin M Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria Eur J Dermatol 2020 30 259 266 10.1684/ejd.2020.3763 32666926 · DOI
  69. [78]Drexel C Bixler E Lee J Lang D Eftekhari S Online education with the patient voice highlights continuous gaps in care and needs for therapeutic options for chronic spontaneous urticaria (CSU) management J Allergy Clin Immunol 2023 151 AB138 10.1016/j.jaci.2022.12.430 · DOI

Cited by

Sorted by citations

Authors
Maurer, M., Albuquerque, M., Boursiquot, J.-N., Dery, E., Giménez-Arnau, A., Godse, K., Guitiérrez, G., Kanani, A., Lacuesta, G., McCarthy, J., Nigen, S., & Winders, T.
Affiliations
  • Humboldt-Universität zu Berlin (DE)
  • CHU de Québec-Université Laval (CA)
  • Fortis Hospital (IN)
  • University of British Columbia (CA)
  • Dalhousie University (CA)
  • Montreal General Hospital (CA)
Corresponding author
Winders, Tonya
ORCID
Venue
Advances in Therapy
Publisher
Springer Science and Business Media LLC
Published
2023-11-22
Volume
41
Issue
1
Pages
14-33
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
DOI
10.1007/s12325-023-02724-6
PMC
PMC10796664
OpenAlex
W4388912340
Cited by
10
References
3
Citations by year
2026: 1 · 2025: 8 · 2024: 1
FWCI
2.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by-nc)
  • Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by-nc)
Funders
Global Allergy & Airways Patient Platform
Topics
  • Health Sciences › Medicine › Rheumatology › Urticaria and Related Conditions
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
Keywords
chronic urticaria, patient charter, patient-provider communication, patient empowerment, self-advocacy, chronic spontaneous urticaria, chronic inducible urticaria, angioedema, quality of life, financial burden, treatment side effects, holistic care, access to specialist care, treatment guidelines
MeSH terms
Chronic Urticaria, Angioedema, Chronic Disease, Humans, Patients, Quality of Life, Urticaria, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review